About Us
NKGen Biotech’s mission is to become the global leader in natural killer cell therapy.
Sangwoo Park
CEO, Chairman, Founder
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in the immune-oncology space and are passionate and excited about the work we are doing to strengthen the immune system.
Executive Leadership
Stephen Chen, MBA
Chief Technical Officer
Yongman Kim, PhD
Chief Scientific Officer, Chief Innovation Officer
Will de Groot, MBA
Chief Business Officer
Steven Cha, MD
Chief Medical Officer
Pierre Gagnon
Chief Operating Officer
Board of Directors
Sangwoo Park
CEO, Chairman, Founder
Stephen Chen, MBA
Chief Technical Officer
Senior Leadership
Paul Chang, MPH
VP, Development Operations
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
Yoonmi Kang
Vice President, Technical Operations
Ryan Park, CFA
VP, Finance & Accounting